Patients concerns about treatment with biosimilars
Biosimilars are not going to be the same as the originator biologic drug and that scares a lot of patients and doctors. They want to see basically the biosimilars treated as new drugs. In this MEDtalk Steve Feldman, professor of dermatology, share his experience with biosimilars.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
